ANI Pharmaceuticals Stock News

ANIP, ARCB and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2023.

ANI (ANIP) delivered earnings and revenue surprises of 11.76% and 8.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI (ANIP) delivered earnings and revenue surprises of 11.76% and 8.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guggenheim launched its coverage on ANI Pharmaceuticals Inc (NASDAQ: ANIP) with a price target of $55 and a Buy recommendation citing a "bullish view" driven primarily by enthusiasm for its Purif

Upgrades According to UBS, the prior rating for Procter & Gamble Co (NYSE:PG) was changed from Neutral to Buy. In the second quarter, Procter & Gamble showed an EPS of $1.59, compared to $1.66 from th

Mirati (MRTX) delivered earnings and revenue surprises of 6.15% and 75.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2022 financia

Results from three major testosterone trials expected in 2023, including the largest testosterone cardiovascular safety/efficacy trials for men and women. AbbVie led Androgel 1.62% 5,246-participant c

ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Judy DiClemente - IR Nikhil Lalwani - President and CEO Steve Carey - CFO Chr

ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ligand (LGND) delivered earnings and revenue surprises of -8.89% and 71.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BAUDETTE, Minn.

Upgrades Macquarie upgraded the previous rating for Netflix Inc (NASDAQ:NFLX) from Underperform to Neutral. Netflix earned $3.20 in the second quarter, compared to $2.97 in the year-ago quarter. At th